Doctoral Programmes and International Networks: Retaining Talent and Creating Value
Developing biotech talent does not mean accumulating qualifications; it means creating people capable of bring together science, data, processes and rules, and to do so in contexts that do not all speak the same language. The doctoral programmes and the international networks serve precisely this purpose: they broaden the methodological horizon, teach you to work with datasets you did not build yourself, require you to negotiate IP and publications, and take researchers beyond the comfort zone of their own school. The point, however, is not “going abroad” in the abstract; it is designing experiences that generate returns: skills, pipelines, protocols and contacts that genuinely change how research and technology transfer are carried out in Italy.
Why a PhD matters (when it is well designed)
A “strong” biotech PhD is not recognised by the number of exams, but by the project quality and by its impact. A sound project has a clear question, a methodology that does not leave everything to chance, and a data plan that respects FAIR principles and a TRL trajectory realistic if the objective is translational or industrial. A PhD candidate should not be an endless apprentice: they should have measurable responsibilities (curated datasets, written protocols, productionised pipelines, experiments that increase statistical power rather than noise). The modern university is not an island; it is a node in a network of laboratories, hospitals, companies, public bodies. When the project is embedded in that network, the qualification stops being a ritual and becomes capital.
Models that really work
The names change, the logic remains: joint supervision when two universities share supervision and standards; industrial doctorates when a company co-designs the work and provides plants, data and real problems; co-funding and secondment when part of a thesis is carried out where the technology actually operates (biobanks, hospitals, supercomputing centres, pilot plants). The international networks make sense when the doctoral researcher does not merely “visit”, but builds together: pipelines that remain in place, SOPs that others will adopt, datasets with a DOI that others will use, protocols for pre-registration that reduce bias and rework.
Anyone working in clinical and health settings must also learn to navigate GCP, MDR/ISO when a device is involved, ethics committees, privacy and consent management; those working on industrial processes need to move through QbD, DoE, PAT, comparability, data integrity; anyone working in AI and bioinformatics must know how to explain the model, not merely make it work, and design monitoring plans for drift that do not end up in a drawer. These are not “bureaucratic complications”: they are the main route to generate robust evidence.
Explore the topics
Mobility that enriches (rather than disperses)
The international mobility is useful when it has a object: skills or results you could not have obtained by staying in one place. Time abroad is worthwhile if you return with something that attaches to your group: a reusable pipeline, a technique that becomes routine, a network of contacts with whom to build a joint project, a piece of regulatory dossier written with those who deal with those practices every day. Collecting passport stamps without leaving a trace is less useful.
How to design healthy mobility: define before the IP scope (Background/Foreground), we agree on deliverable that will remain available on return, we build a data plan with roles and access rights (DPA where personal data are involved), we plan co-supervision real (meetings, results reviews, rights and duties), consideration is given to how to manage open science and embargo if there is a risk of losing patent novelty. This avoids discovering at the end that the results “cannot be used”.
Knowledge transfer: from notebook to practice
Transferring knowledge means document it and put it into operation. A doctoral researcher who returns from an international network and can write a SOP that the laboratory adopts, that sets up a recipe library versioned for a bioreactor, which publishes a pipeline reproducible with tests and example datasets, has created value. Anyone who has worked with clinical data must know how to close a Data Management Plan that the organisation understands and monitor audit trail and quality; those who have worked on devices must be able to deliver MDR requirements, validation plans and usability protocols. Knowledge transfer is measured by how many things are do things differently afterwards, not by the number of slides.
IP, publications and timing: a possible balance
Biotech also means IP. If there is a patentable idea, it is files first before disclosing (including posters, preprints and public seminars). The fear of “losing the publication” is often unfounded: by coordinating legal, supervisors and partners, novelty and is published in any case, with compatible timelines and level of detail. When the advantage lies in the trade secret, we work on controlled-access processes: who can see what, with which logs, how change and versioning. In all cases, the doctoral researcher learns that a scientific claim and a IP claim are two ways of describing the same reality; if they conflict, the project is fragile.
Networks that last: alumni, visiting appointments, joint projects
Networks are not events: they are operational relationships. What works are the alumni network that keep technical channels alive (thematic mailing lists, small working group call quarterly on common issues), the visiting scientist who arrive to do something concrete (upload a dataset, reproduce an experiment, validate an algorithm), the joint projects with lightweight governance and clear objectives. The circulation of people: students who go abroad and return, researchers who spend a semester in a plant, company technologists who spend weeks in the laboratory. When the scope is clear, trust grows and timelines shorten.
How do you retain talent (without vague promises)
People stay when they can grow and observe an effect. This requires two things: non-ornamental projects and career paths readable. Young professionals want hands-on experience with data and processes, not to spend years waiting for authorisation or repeating the same experiment. You need a mentoring that explains how the world works outside the paper, structured access to infrastructure (biobanks, plants, supercomputing), micro-budget discretionary for targeted initiatives, recognition when a pipeline or SOP begins to make a difference. And a role ladder: from those who lead a small project unit to those who become a bridge to industry or regulators.
Measuring impact: beyond the h-index
There is an honest way to understand whether doctoral programmes and networks are working: look at what has changed. How many dataset have been made reusable and used by third parties? How many pipeline held up outside the laboratory that produced them? How many SOP reduced times or errors? How many cases have gained a scientific advice solid or a comparability without rework? How many collaborations led to products, prototypes, trials? How many talent remain, with roles that also help others grow? This is the dashboard that matters, not the average impact factor.
Where Technoscience comes in
Within our ecosystem biotech doctoral programmes and international networks are not showcases, but value-building initiatives. We support universities, IRCCSs and companies in project design (scientific and industrial question, methods, data, TRL), in network governance (IP, privacy, MTA, licensing, open science vs trade secrets), in implementing biobanks, data platforms, telemedicine and pilot plants that make the doctorate genuinely industrial. On return, we turn the results into published pipelines, adopted SOPs, protocols that become routine practice and industrial pathways that get started, alongside modular training programmes on QbD, DoE, data integrity, applied bioinformatics and regulatory affairs: so that those returning from an international network do not speak a language the team cannot understand, but bring marketable biotech skills.
Choose Technoscience!
If you are designing or rethinking an industrial PhD or an international biotech network, use this form to request a programme fit check. In a few lines, tell us who the partners are, what scientific and industrial objectives you have set, how data, clinical sites or plants are organised, and what concrete outcomes you expect (publications, patents, protocols, career pathways). We will contact you for an operational call: we will identify the project’s strengths and gaps, propose an architecture for governance and value return (for talent, organisations and companies) and, where appropriate, a set of training modules and data-governance tools that make the PhD or international network a genuine engine for biotech talent, not just a line on a CV.
Frequently Asked Questions
The questions you ask us most often
Search adherence between what you want to learn and what that network actually does every day. Question: will I return with a pipeline, a dataset, or a technique that we will actually use? If the answer is no, change network or redesign the objective.
Yes, but files first. Novelty is a binary switch: a public disclosure before filing turns it off. By coordinating timing and content, it is possible to protect and publish without losing value.
Just enough to complete a deliverable non-trivial (pipeline, dataset, protocol). Three months with an adopted outcome is better than a year “spent observing”.
When the company provides real problems, access to data/plants, a technical supervisor that exists, and when the project produces artefacts that remain (SOPs, recipes, models). If the industrial component is only a letter of intent, it is not an industrial doctorate.